HIPK2

Rila Therapeutics Exits Stealth Mode

Retrieved on: 
Thursday, October 27, 2022
Kidney, Informatics, SAN, Medicine, American Society for Clinical Investigation, HIPK2, School, San Francisco Bay Area, Dialysis, Mount Sinai Health System, Industry, Technology, Doctor of Philosophy, Icahn School of Medicine at Mount Sinai, FDA, Therapy, Patient, MD, IND, Knowledge, Artificial intelligence, Research, Kidney disease, CEO, Society, Hospital, Associate, Nursing, Geriatrics, Health, NIH, American Association of Physician Specialists, Pharmaceutical industry, Nephrology, Physician

SAN FRANCISCO, Oct. 27, 2022 /PRNewswire/ -- Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, today announced its emergence out of stealth mode.

Key Points: 
  • SAN FRANCISCO, Oct. 27, 2022 /PRNewswire/ -- Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, today announced its emergence out of stealth mode.
  • "I am thrilled Rila Therapeutics will be moving forward with IND enabling studies as this therapy is a novel first-in-class treatment for renal fibrosis," said Dr. Bob Drakas, CEO of Rila Therapeutics and President of ShangPharma Innovation.
  • The small molecule targeting HIPK2 is based on technology developed by Mount Sinai faculty and licensed to Rila Therapeutics.
  • Rila Therapeutics mission is to improve the lives of patients suffering from renal fibrosis by providing a safe and effective anti-fibrotic therapy.

Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

Retrieved on: 
Tuesday, December 14, 2021
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Science, Clinical Trials, TRRAP, Personalized medicine, Clinical trial, MDS, Abstract, AZA, Disease, CBM, Drug resistance, Antigen, Biosimulation, HMA, Biomarker, Artificial intelligence, Myelodysplastic syndrome, CAV1, DAC, KDM4C, IFNA1, JAK2, MD, ASH, Society, Monosomy, Group, HIPK2, Research, Exposition, Agilent Technologies, DNA, VPA, HDAC, Software, Drug combination, Sequoia Capital, GSK3B, CD8, CTNNB1, Immunology, Azacitidine, UnitedHealth Group, Escape Room, Neoplasm, Patient, CD274, Medical device, Vaccine, Pharmaceutical industry, Decitabine

In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.

Key Points: 
  • In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
  • Cellworks Biosimulation Platform found that signaling pathway consequences related to CTNNB1 and c-MYC modulation predict response to DAC + VPA.
  • Biosimulation using the Cellworks Computational Omics Biology Model (CBM) identifies immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.